Cover Image
市場調查報告書

Glipizide的中國市場

Investigation Report on China Glipizide Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 335237
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Glipizide的中國市場 Investigation Report on China Glipizide Market, 2010-2019
出版日期: 2015年07月10日 內容資訊: 英文 30 Pages
簡介

2014年的中國Glipizide市場上,Pfizer以銷售額為準獲得86%的巨大佔有率,殘餘的14%的佔有率由Shandong Wanjie High-tech Co., Ltd、Yangtze River Pharmaceutical Group、Disha Pharmaceutical Group等企業分享。

本報告提供中國的Glipizide的市場相關調查、Glipizide的功效、效果、中國市場中專利及核准狀況、銷售額、銷售量的變化與預測、價格趨勢、主要製造商與市場佔有率、競爭環境與其展望、主要製造商簡介等彙整資料。

第1章 Glipizide的相關概念

  • 適應
  • 全球市場的銷售情形

第2章 中國的Glipizide的市場簡介

  • 專利情形
  • 主要製藥公司
  • 市場規模

第3章 中國的Glipizide銷售情形

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售數

第4章 中國的Glipizide的主要製藥公司市場佔有率

  • 銷售額為基礎的的市場佔有率
  • 銷售量為基礎的的市場佔有率

第5章 中國的Glipizide的劑型的相關調查

  • 各劑型的市場佔有率:銷售額為基礎的
  • 各劑型的市場佔有率:銷售量為基礎的

第6章 中國醫院的Glipizide的標準價格

  • Pfizer (US)
  • Shandong Wanjie High-tech Co., Ltd
  • Yangtze River Pharmaceutical Group
  • Disha Pharmaceutical Group
  • Hangzhou Conba Pharmaceutical Co., Ltd
  • Shanghai Sine Pharmaceutical Co., Ltd

第7章 中國市場中Glipizide的主要製藥公司

  • Pfizer (US)
  • Shandong Wanjie High-tech Co., Ltd
  • Yangtze River Pharmaceutical Group
  • Disha Pharmaceutical Group
  • Hangzhou Conba Pharmaceutical Co., Ltd

第8章 中國Glipizide的市場預測

  • 市場規模的預測
  • 競爭情形的預測
目錄
Product Code: 1507262

According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.

As one of the earliest oral antidiabetic drugs, sulfonylurea is common to patients with insulin hyposecretion. By stimulating insulin secretion, sulfonylurea is able to reduce blood glucose. According to the length of action, sulfonylurea can be categorized into short-acting, medium-acting and long-acting preparations. And glibenclamide, gliquidone, glipizide and glimepiride are the common drugs in the class of sulfonylurea.

As the first-line drug for type 2 diabetes, glipizide belongs to the second generation of sulfonylurea and it works by stimulating insulin secretion. Developed by Pfizer, glipizide was approved by FDA to enter the market in Apr. 1994. Glipizide in the Chinese market mainly comes from Pfizer (Trade Name: Glucotrol Common Name: Glipizide Controlled Release Tablets), Disha Pharmaceutical Group (Trade Name: Dishapian Common Name: Glipizide Tablets) and Yangtze River Pharmaceutical Group (Trade Name: Qinsu Common Name: Glipizide Extended Release Tablets). Although quite a lot local enterprises produce gliclazide, they all took up a small market share.

According to CRI's market survey, in 2014, Pfizer (US) took up a market share of about 86% for sales value in China while other companies like Shandong Wanjie High-tech Co., Ltd, Yangtze River Pharmaceutical Group and Disha Pharmaceutical Group shared the rest market share. The annual sales value of glipizide stays at CNY 50-60 million during the period of 2005-2014.

The market size of glipizide is expected to stay at a certain level in the next few years in China.

Readers can get at least the following information through this report:

  • market size of glipizide in China
  • major manufacturers of glipizide for Chinese market and their market share
  • retail price of glipizide in Chinese market
  • market outlook of glipizide in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-diabetic drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Glipizide

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Glipizide in China

  • 2.1. Patent Status
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Glipizide in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Glipizide in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Glipizide in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Glipizide in Chinese Hospitals in 2014

  • 6.1. Pfizer (US)
  • 6.2. Shandong Wanjie High-tech Co., Ltd
  • 6.3. Yangtze River Pharmaceutical Group
  • 6.4. Disha Pharmaceutical Group
  • 6.5. Hangzhou Conba Pharmaceutical Co., Ltd
  • 6.6. Shanghai Sine Pharmaceutical Co., Ltd

7. Major Manufacturers of Glipizide in Chinese Market, 2010-2014

  • 7.1. Pfizer (US)
  • 7.2. Shandong Wanjie High-tech Co., Ltd
  • 7.3. Yangtze River Pharmaceutical Group
  • 7.4. Disha Pharmaceutical Group
  • 7.5. Hangzhou Conba Pharmaceutical Co., Ltd

8. Market Outlook of Glipizide in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Registration Information of Glipizide in China
  • Chart Approval Status of Glipizide in China
  • Chart Sales Status of Glipizide in China, 2010-2014
  • Chart Sales Value of Glipizide in China, 2010-2014
  • Chart Sales Value of Glipizide by Regions in China, 2010-2014
  • Chart Sales Value of Glipizide Tablets in China, 2010-2014
  • Chart Sales Value of Glipizide Capsules in China, 2010-2014
  • Chart Market Share of Major Manufacturers of Glipizide for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Glipizide Made by Pfizer (US) in China, 2010-2014
  • Chart Sales Value and Market Share of Glipizide Made by Shandong Wanjie High-tech Co., Ltd in China, 2010-2014
  • Chart Sales Value and Market Share of Glipizide Made by Yangtze River Pharmaceutical Group in China, 2010-2014
  • Chart Sales Value and Market Share of Glipizide Made by Disha Pharmaceutical Group in China, 2010-2014
  • Chart Price of Glipizide Made by Pfizer (US) in Some Chinese Cities in 2014
  • Chart Price of Glipizide Made by Shandong Wanjie High-tech Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Glipizide Made by Pfizer (US) in Some Chinese Cities in 2014
  • Chart Price of Glipizide Made by Disha Pharmaceutical Group in Some Chinese Cities in 2014
  • Chart Price of Glipizide Made by Hangzhou Conba Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Glipizide Made by Shanghai Sine Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Back to Top